High-dosage, tocolytic magnesium sulfate (MgSO 4 ) administered to pregnant women during preterm labor can be toxic, and sometimes lethal, for their newborns (Cochrane Database of Systematic Reviews (relative mortality risk 2.82, 95% confidence interval 1.2-6.6)). Based on the results of the Magnesium and Neurologic Endpoints Trial and the work of many others, a unifying triangular concept is proposed to account for the increased prevalence of brain lesions, with their likely resultant mortality, in neonates and infants exposed to high-dose MgSO 4 in the context of preterm labor. We review the evidence that: (1) elevated circulating levels of serum ionized magnesium occurring in mothers, and therefore in their babies, at the time of delivery are associated with subsequent neonatal intraventricular hemorrhage (IVH); (2) neonatal IVH is strongly associated with lenticulostriate vasculopathy (LSV), an unusual mineralizing lesion involving the thalami and basal ganglia of the neonate; and, (3) exposure to 50 g or more of tocolytic MgSO 4 during preterm labor is associated with the development of LSV.
Introduction
High-dose magnesium sulfate (MgSO 4 ) administered to pregnant women during preterm labor can be toxic, if not lethal, for some of their newborns. 1 The Magnesium and Neurologic Endpoints (Randomized Clinical) Trial (MagNET) had been conducted to explore whether pharmacologic doses of MgSO 4 , used mostly as a tocolytic, could prevent cerebral palsy (CP) in children. At 15 months into the study, MagNET was halted by the Institutional Review Board at the University of Chicago because of excess total pediatric mortality (i.e., fetal þ neonatal þ postneonatal) following exposure to tocolytic doses of MgSO 4 (risk difference 15.2, 95% confidence interval (CI) 4.4-26.0%; P ¼ 0.01). Since then, we have continued to examine the data set of MagNET in order to better understand the pathophysiology of magnesium-related morbidity and mortality.
Based on the results of these subsequent studies and those of others, we now propose a unifying, three-sided concept that provides an explanation for the increased prevalence of brain lesions, as well as mortality, in preterm infants exposed to highdose MgSO 4 in the context of preterm labor. First, elevated circulating levels of serum ionized magnesium (iMg) occurring in mothers, and therefore in their babies, at the time of delivery are associated with subsequent neonatal IVH. 2 Second, IVH is strongly associated with lenticulostriate vasculopathy (LSV), an unusual mineralizing lesion involving the thalami and basal ganglia of the neonate. 3 Third, exposure to 50 g or more of tocolytic MgSO 4 during preterm labor is associated with the development of LSV. 4 Of interest, doses of MgSO 4 in this range, such as those used in tocolysis, have also been shown to be associated with total pediatric mortality in the Cochrane Database of Systematic Reviews (relative risk (RR), 2.82, 95% CI 1.2-6.6). 5 
Initial magnesium and CP hypothesis
The initial hypothesis that exposure to antenatal MgSO 4 in the context of preterm labor could prevent CP came from a casecontrol study of children in the California Birth Defects Surveillance Program. 6 In that report, only 7% of 42 very low birth weight (VLBW, <1500 g) newborns with CP had been exposed as fetuses to antenatal MgSO 4 , compared to a 36% exposure rate among controls (odds ratio (OR) 0.14, 95% CI 0.05-0.51). However, the clinical data used in the study were abstracted retrospectively from medical records. Thus, the potential for incorrect or incomplete data reporting may have led to bias, that is, the findings may have been confounded by one of the maternal indications for the usage of MgSO 4 , viz., preeclampsia. 7 Out of 18, 13 (72%) preeclamptic mothers, but only 30 of 99 (30%) of women without preeclampsia, had been given MgSO 4 . The authors rightly state that this made 'it impossible to evaluate preeclampsia and magnesium independently'. 6 Preeclampsia, as a pathophysiologic condition, is now known to be associated with fewer adverse neurologic outcomes in newborns than other obstetric complications, such as the fetal inflammatory response syndrome, so often seen in preterm premature rupture of the membranes. 8 In one recent study conducted outside the United States among preeclamptic mothers, virtually none of whom had received MgSO 4 prophylaxis, no child was later found to have cystic periventricular leukomalacia (cPVL), an important risk factor for subsequent CP. 9 Thus, despite the absence of magnesium exposure, there appears to be some, as yet to be characterized, biological factor in the pathogenesis of maternal preeclampsia that is inherently neuroprotective for babies. One such factor might be the absence of intrauterine infection.
Nonetheless, before much of the preceding information was known, the report from California 6 generated considerable interest in MgSO 4 as a potential 'silver bullet' to prevent CP. Magnesium would have been convenient because it is so inexpensive and widely used as a tocolytic in some countries, such as the United States, despite any convincing evidence for that indication.
5,10 -13 As we have since learned from evidence-based studies, it is, however, quite properly indicated for seizure prophylaxis in preeclampsia. [14] [15] [16] [17] On the other hand, multiple observational studies concerning the possible influence of MgSO 4 on neonatal white matter damage have not supported the hypothesis that MgSO 4 might be effective neuroprophylaxis in preterm infants. 18 As it happened, the observed protective effect became smaller as the number of subjects in the study became larger. Moreover, in a second follow-up study, when excluding pregnancies with preeclampsia, the California data set investigators were unable to confirm the original CP hypothesis concerning a possible protective effect for MgSO 4 .
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The MagNET Trial Nonetheless, in 1995, our own high expectations, and absence of what is now, to be certain, a hard-earned and perhaps more sophisticated understanding of the toxicity that can be associated with high-dose magnesium, led us to a decision to conduct a randomized controlled trial (RCT) of MgSO 4 as a simple intervention to prevent CP. In this study, the Magnesium and Neurologic Endpoints Trial (MagNET), 1, 20 women in active preterm labor (defined as progressive effacement and dilatation of the uterine cervix at <34 completed weeks of gestation) were randomized into one of two treatment groups based on cervical dilatation at the time of their hospital admission. Those who were less than 4 cm dilated were randomized to either tocolytic MgSO 4 or to other tocolytics (terbutaline, ritodrine, nifedipine, or indomethacin). Mothers with cervices more dilated were randomized to receive either 4 g of intravenous magnesium (for putative low-dose neuroprotection) or physiological saline. Women with preeclampsia were excluded from MagNET in order to eliminate unnecessary confounding (see above).
We collected obligatory data on numerous epidemiologic risk factors, and obtained various biological specimens at delivery. Among the latter were samples of maternal and umbilical cord venous blood, drawn at the time of delivery, for the later determination of serum iMg levels. 2, 20, 21 To learn whether evidence for the fetal inflammatory response syndrome (FIRS) might be a factor in our outcomes, we also (a) evaluated umbilical cord bloods at delivery, looking for a specific inflammatory cytokine, interleukin-6 (IL-6), and (b) determined whether or not histologic funisitis (transmural migration of neutrophils from the vascular lumina through the muscularis of one or more umbilical cord blood vessel walls) was present. [22] [23] [24] During the first month after delivery, babies underwent head ultrasound scans (HUS) obtained in weeks 1, 2, and 4 of life. The identification of neurologic abnormalities was made by two experienced pediatric radiologists who were well versed in identifying both IVH and LSV because of their previous work. 25 The final diagnosis and grading of IVH, 26 as well as the recognition of LSV, was made by consensus. Both neuroradiologists were masked, as far as possible, to antecedent clinical information. To determine adverse medical and neurological clinical outcomes, follow-up examinations were conducted for surviving members of the cohort at 4, 8, 12, and 18 corrected months of age in especially designated clinics. The diagnosis of CP was carried out and Bayley Psychomotor Development Index (PDI) Scores 27 were determined and assigned by a developmental pediatrician at the 18-month visit.
Mortality in MagNET
Only 15 months into the study, the trial was suspended by the Institutional Review Board. An interim Data and Safety Monitoring analysis by the United Cerebral Palsy (UCP) Research and Educational Foundation) had shown a remarkable excess in total pediatric mortality among the babies of mothers who had been randomized to tocolytic MgSO 4 . Overall, in the entire trial, including data from both arms of the study, by intent-to-treat analysis, there were 10 deaths in the MgSO 4 arms, whereas there was only one death in the control arms (mortality risk difference, 10.7, 95% CI 2.9-18.5%; P ¼ 0.02). Of nine deaths following an actual, not just theoretical, exposure (all occurred in the MgSO 4 arms and all underwent autopsy), one was a fetal death, four occurred neonatally (p28 days of age), and four occurred in the post-neonatal period (>28 days of age, but <365 days of age). The attributable causes of death were: sudden infant death (n ¼ 3); congenital anomalies (n ¼ 1); twin-to-twin transfusion donor or recipient (n ¼ 2); neonatal apnea (n ¼ 1); respiratory arrest (n ¼ 1); and cardiopulmonary arrest (n ¼ 1). 1 Although a common thread possibly linking these mortalities was not apparent at that time, it has now become more understandable, as we will discuss below.
Subsequent analyses of the biological variables collected at delivery confirmed the observed association between exposure to MgSO 4 and total pediatric mortality. Among seven babies on whom we had collected umbilical cord blood, and who ultimately died, the median umbilical cord blood iMg level was found to be 0.76 mmol/l, as compared to a median cord blood level of 0.55 mmol/l among 75 survivors (Mann-Whitney U-test, P ¼ 0.03). Using multivariable regression to control for possible confounding, the association between higher levels of circulating iMg and deaths in babies remained statistically significant (adjusted (adj) OR 7.7, 95% CI 1.2-47.6; P ¼ 0.03). 21 Thus, we confirmed the relationship between MgSO 4 exposure and unexpected deaths by showing that initial systemic iMg levels were indeed (on average) higher in children who later died than in children who survived.
iMg and neonatal IVH While searching for explanations of the observed association between MgSO 4 and mortality, we found that higher levels of iMg circulating in the mothers' blood at the time of delivery were significantly associated with IVH in their babies. 2 Among 144 babies in MagNET who survived long enough to undergo a head ultrasound as specified by the research protocol, 24 had neonatal IVH (Grade I, n ¼ 19; Grade II, n ¼ 0; Grade III, n ¼ 5; and Grade IV, n ¼ 0). Among women whose babies had IVH, the mean maternal venous serum iMg level was 0.75 mmol/l, whereas among mothers whose babies did not develop IVH the mean serum iMg level was 0.56 mmol/l (P ¼ 0.01). We confirmed that higher magnesium levels were a significant predictor for neonatal IVH even when adjusting for confounders (adj OR 15.8, 95% CI 1.4-175.0). (In 1997, Stigson and Kjellmer 28 had been the first to report an association between serum-iMg levels and IVH. In a sample of 69 infants who were less than 32 weeks in gestational age, serum magnesium levels were higher in infants with lowgrade IVH (but not high grade) than in controls.)
Our finding that higher levels of magnesium were significantly associated with bleeding into the ventricles of babies prompted us to actively explore the possibility that advanced neonatal IVH may, in turn, account for a portion of the increased total pediatric mortality seen in MagNET. Among babies who underwent cranial ultrasonography, but who eventually died, 25% (two of eight) had Grade III IVH, whereas 2.2% (three of 136) of survivors had a Grade III lesion (OR 14.8, 95% CI 2.5-91.9; P ¼ 0.025). Moreover, the mean serum iMg levels at delivery among mothers whose babies had Grade III IVH was 1.00 mmol/l, while it was 0.67 mmol/ l among those whose babies had Grade I IVH (not significant). Since high-grade IVH is more likely to be associated with an increased risk of mortality, such as those potentially mediated by apnea, than is low-grade IVH among infants with similar levels of illness severity, 29 our observation of a possible 'dose-response' relationship may be of particular importance.
Lenticulostriate vasculopathy
Neonatal LSV, also known as mineralizing vasculopathy, is diagnosed by cranial ultrasonography. By definition, LSV consists of bright, echogenic, linear blood vessels in the basal ganglia and thalami. Neuropathological correlates of LSV include thickened and hypercellular blood vessel walls having intramural and perivascular mineralization, 30 as well as adventitial or subendothelial deposits of amorphous, basophilic material in small-and medium-sized arteries. 31 Of interest, LSV was first reported in the 1960s after a congenital rubella epidemic in Philadelphia. 32 Postmortem histology of the brains from affected babies showed a highly regionalized vasculitis. For reasons still unknown, the pathologic lesion was limited exclusively to the thalami and basal ganglia.
In the 1980s, Teele et al. 33 looked carefully for this lesion during their retrospective study of nearly 4500 HUS's at Boston Children's Hospital. They found 12 previously unreported cases of neonatal LSV; eight babies had congenital infections (cytomegalovirus, n ¼ 5; rubella, n ¼ 2; and, syphilis, n ¼ 1), three had trisomy in the absence of apparent infection, and one infant had no pathologic diagnosis. In all four autopsied babies, thalamic blood vessels with basophilic deposits consistent with mineralization and hypercellularity were found. Thus, focal vasculopathy appears to be the neuropathologic substrate of the linear echogenicity seen on HUS. 33 When this study was carried out, that is, in the time frame of the observed cases, MgSO 4 was not as widely used for tocolysis in the United States as it is today.
LSV in MagNET
Among 140 babies from MagNET on whom we have both neonatal IVH and LSV data, LSV was present in 14 (10%). IVH was also present in 14 babies (10%). Given the principle that the joint probability for the occurrence of two independent events is their mathematical product (here: 0.1 (10%) Â 0.1 (10%) ¼ 0.01 (1%)), our finding that the joint probability of LSV and IVH was 5% (seven of 140), not 1%, indicates that the occurrences of LSV and IVH are not independent. Indeed, IVH was present in seven of 14 with LSV (50.0%; Grade I, n ¼ 5; Grade III, n ¼ 2), and in only seven of 126 (5.6%) without LSV (P ¼ 0.003).
Using multivariable logistic regression analysis, we controlled for the possible confounding of the association between LSV and neonatal IVH by other important risk factors, such as low birth weight, a well-documented predictor of IVH. However, adjustment for other antenatal variables did not alter the significant relationship between IVH and LSV (adj OR, 9.8; 95% CI 1.3-73.1; P ¼ 0.03). When looking at severity of IVH, we found that 14.3% (two of 14) babies with LSV had IVH Grade III, whereas 1.6% (two of 126) of babies without LSV had high-grade disease. This suggests that IVH might be more severe when LSV is present. Conversely, LSV may be a marker for severe IVH.
We could not find any differences in the maternal and demographic variables between newborns who had LSV and those without it. None of the babies had clinical evidence for congenital infections (rubella, CMV, or syphilis). Only one baby with LSV had major congenital anomalies (esophageal atresia with a distal tracheo-esophageal fistula, ventricular septal defect, and 13 left ribs), and none of those babies with LSV had chromosomal abnormalities. Among 22 obstetrical variables we evaluated, only Apgar One <7 (P ¼ 0.01), noncephalic presentation of a singleton or sibling A of twins (P ¼ 0.04), and total MgSO 4 exposure X50 g (P<0.048) significantly predicted the occurrence of LSV on univariate analysis. (The decision to dichotomize exposure at the threshold of about 50 g or more was based on our previous work, 34, 35 as well as the clinical trial experience from another group of investigators. 36 ) Among these variables, only the receipt of high-dose MgSO 4 remained statistically significant (adj OR 8.3, 95% CI 1.5-45.0, P ¼ 0.01) in multivariable logistic regression.
To exclude the possibility that LSV results from postnatal, not antenatal, events, we performed additional analyses to adjust for possible confounding risk factors occurring in the neonatal intensive care unit. Among neonatal variables, patent ductus arteriosus (P ¼ 0.07) and need for ventilator usage (P ¼ 0.08) were marginally significant. However, in a multivariable logistic regression, only high-dose MgSO 4 exposure remained significant. Thus, the etiology of LSV is more likely to be a sequel to antenatal risk factors, as opposed to events occurring after delivery.
Magnesium clearance in babies
Can biological mechanisms explain the association between magnesium and LSV or IVH? As it happens, magnesium is likely to be actively transported by the placenta from the maternal to the fetal circulation. 37 Using data from the MagNET Trial, we found that iMg levels are about 13% higher in umbilical cord venous serum (mean level 0.52 mmol/l) than in paired maternal venous serum at delivery (0.46 mmol/l; P ¼ 0.004). Others have made similar observations. 38 Moreover, we found that the magnesium gradient was even greater (17%; P ¼ 0.001) in the setting of MgSO 4 tocolysis. 39 Thus, although obstetricians tend to make clinical decisions based on circulating magnesium levels in the mother, those in the fetus appear to be substantially higher and, thus, potentially more harmful, especially given the current state of our evolving knowledge.
In addition, using a separate, comprehensive data set collected over a several-year period at the Neonatal Intensive Care Unit at the University of Chicago Children's Hospital, we found that high levels of magnesium are cleared very slowly by newborns. Among babies (n ¼ 49) whose mothers had been exposed to antenatal MgSO 4 as prophylaxis for preeclampsia (thus receiving magnesium at the time of the delivery), and for whom levels of total serum magnesium (TMg) were available on day 0 (day of birth), the mean total serum (TMg) was found to be 4.4 mg/dl (absolute maximum 'normal' value as per University of Chicago laboratory standard: 2.5 mg/dl). By day 5 of life, the mean TMg value was 2.7 mg/dl, still well above the absolute maximum 'normal' value. Among VLBW infants (n ¼ 58), the median daily clearance of magnesium was 9.4% of the total circulating amount, whereas among larger infants (n ¼ 65) the median daily clearance was 11.1%. The difference was significant (Mann-Whitney U-test, P ¼ 0.03). 40 Thus, babies who had been exposed to antenatal MgSO 4 were: (1) born with high serum levels of magnesium, (2) the magnesium was cleared very slowly, and (3) the smallest and most vulnerable babies cleared magnesium at a rate even more slowly than did their heavier and more robust peers.
Outcomes and mechanisms
The neurological implications for infants who have LSV are not well established. Moreover, we are not aware of any long-term neurologic follow-up study comparing neonates who have LSV to babies without the lesion. However, babies with LSV who have a readily identifiable underlying condition appear to have a high risk for long-term neuropsychiatric limitations. 41 On the other hand, the potential neurological sequelae of IVH are already well known. 42 As of the moment, however, it is still unknown whether the simultaneous occurrence of LSV and IVH yield neurological consequences different from those of IVH alone.
Concerning biological mechanisms, we postulate that the association between magnesium and neonatal IVH could be due to the clinically relevant anticoagulant properties of magnesium mediated through its complex interaction with platelets and other components of hemostasis. [43] [44] [45] With regard to LSV, MgSO 4 may have a direct effect on causing either cellular infiltration or calcium deposition in the lenticulostriatal vasculature or in its supporting matrix. Moreover, magnesium, a calcium antagonist, has well-recognized relaxing effects on arterial smooth muscle by decreasing the levels of intracellular calcium. 46 It is, however, unknown whether it might cause inflammation or calcium deposition in vessels.
In the laboratory Although magnesium has been found to be protective against brain damage in limited experimental settings via diminished neuronal apoptosis, 47 decreased neuronal loss with imposed ischemia, 48, 49 and reduced oxidative neuronal damage, 50, 51 other studies have not shown any benefit. [52] [53] [54] [55] [56] In the laboratory, the research findings seem to differ according to the animal species used for experimentation, and the kind of artificial insult used to initiate the biological injury. In immature rat pups, a dose-dependent reduction of intrastriatal N-methyl-D-aspartate-induced excitotoxic brain damage was reported after intraperitoneal application of MgSO 4 occurring 15 min or longer after the initiation of the artificial insult. 57 Conversely, in an excitotoxic model of brain injury using mice pups, intraperitoneal MgSO 4 reduced the ibotenate-induced brain damage, if administered on the fifth postnatal day, but not if given at birth. 58 In all, 18 of 20 pups coinjected at birth with both MgSO 4 and ibotenate developed small cystic white matter lesions that were not seen in animals injected with ibotenate alone. As mentioned previously, in the human, cystic lesions in the white matter of the brain (cPVL) are known to be highly associated with CP. 59 
Caveats
Our suggestion that brain lesions and unexpected mortality may be due to high-dose MgSO 4 exposure in the setting of preterm labor does not necessarily preclude the possibility of a neuroprotective role for low-dose magnesium. Findings from the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO 4 ) have shed some light on this intriguing notion. 60 In that study, about 1000 children were enrolled, on whom the effect of prophylactic MgSO 4 (in a total maximum dosage of 28 g) was assessed when given immediately prior to delivery in women with complicated preterm pregnancies (<30 completed gestational weeks). Gross motor dysfunction was reduced among those randomized to MgSO 4 (17.0%), as opposed to those given placebo (22.7%) (RR 0.75, 95% CI 0.59-0.96). However, the differences between magnesium and placebo exposure in regard to CP were small and not significant (6.8 versus 8.2%, respectively, P ¼ 0.38). A further limitation of ACTOMgSO 4 is the inclusion of some mothers with preeclampsia into the randomization scheme, which again brings up the issue of confounding, as in the California Birth Defects study. 6 Quite recently, the Premag Trial Group (13 French research centers) reported the results of its national RCT. 61 More than 500 women were randomized to receive either intravenous MgSO 4 4 g or saline control. For the primary outcome variable of severe white matter injury, no significant difference was found between the two groups (9.7 versus 11.8%, respectively; OR 0.73, 95% CI 0.46-1.28). However, despite the use of randomization, the authors suggested that the unbalanced, higher prevalence of preterm premature rupture of the membranes and maternal-fetal inflammatory conditions in the MgSO 4 exposed group could have had a muting effect on any differences that might otherwise have been present.
In the United States, the Beneficial Effects of Antenatal Magnesium (BEAM) Trial is now being brought to a conclusion by the National Institute of Child Health and Human Development (NICHD, NIH). BEAM is a trial in which the ideal prophylactic MgSO 4 dose is meant to be 30 g. Given that BEAM is about twice the size of ACTOMgSO 4 (n ¼ 2000) and the hoped-for exposure doses to MgSO 4 are comparable (30 versus 28 g), the increased power generated by the larger samples in BEAM may ultimately permit us to infer that MgSO 4 , when used as a prophylactic in preterm labor, but not as a tocolytic, may be neuroprotective. But this hypothesis, although very attractive, remains decidedly unproven.
In closing
Regardless of the final results from yet incomplete and unreported studies, the continued injudicious use of high-dose tocolytic MgSO 4 cannot be supported. To date, the data indicating an association, at large doses, with pediatric neuronal injury and death, as has been shown in the Cochrane Database of Systematic Reviews, 5 and our own published research 1, 20, 34, 35 far outweigh the data indicating pediatric health outcome benefit. 62 It is, on the other hand, conceivable that, in the setting of preterm labor, the combination of an evidence-based tocolytic with low doses of MgSO 4 (if, in fact, low dose, magnesium is found to be neuroprotective), as well as, perhaps, drugs such as aminophylline, 63 could simultaneously delay delivery in some women having preterm labor, while, at the same time, protecting the developing nervous system of their babies. The proper testing of this concept would require the conduct of well-designed, randomized clinical trials. To our knowledge, no such trials are currently underway or being planned. Thus, a research opportunity possibly exists in the future for courageous investigators who are committed to the well being and improved neurological functioning of our smallest and most vulnerable children. But, when conducting such a trial, we must assiduously follow the long-term well being of the cohort to determine if any adverse pediatric outcomes occur. And, as always, we must continue to observe one of the most sacred principles of our profession, 'Primum non nocere.'
